Identifying prognosis and metastasis‑associated genes associated with Ewing sarcoma by weighted gene co‑expression network analysis

Wang,Ben; Li,Jie; Li,Xin; Ou,Yunsheng

doi:10.3892/ol.2019.10681

Identifying prognosis and metastasis‑associated genes associated with Ewing sarcoma by weighted gene co‑expression network analysis

Authors:
- Ben Wang
- Jie Li
- Xin Li
- Yunsheng Ou
View Affiliations

Affiliations: Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China, Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China
Published online on: July 29, 2019 https://doi.org/10.3892/ol.2019.10681
Pages: 3527-3536
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ewing sarcoma (ES) is a highly malignant pediatric tumor with a low survival rate and a high rate of metastasis. However, there have been limited reports on the exploration of new biomarkers of ES. Therefore, the aim of the present study was to identify the potential hub genes associated with overall vital survival (OVS) and metastasis in ES. Traditional methods for identifying differentially expressed genes lack the in‑depth information of mechanistic studies. In this study, a weighted co‑expression network for ES was constructed through weighted gene co‑expression network analysis to identify co‑expression modules associated with clinical phenotypes. The hub genes in the metastasis‑ and OVS‑related co‑expression modules were extracted, and the association between the hub genes and patient OVS was verified in another independent Gene Expression Omnibus dataset. Functional annotations and protein‑protein interaction analysis of co‑expression modules were also used to understand the potential regulatory mechanisms. The results of the functional enrichment analysis revealed that the OVS‑associated module was mainly enriched in the cell cycle and immune response, and the metastasis‑associated module was enriched in metabolism. A total of four genes (proteasome subunit α4, L1 cell adhesion molecule, serine/threonine kinase receptor‑associated protein and cytotoxic T‑lymphocyte‑associated protein 4) in the OVS‑related module and two genes (calcium voltage‑gated channel auxiliary subunit γ2 and γ‑aminobutyric acid type B receptor subunit 2) in the metastasis‑related module were selected as hub genes. Further research on the hub genes identified in the present study may contribute to the understanding of the mechanism of ES metastasis and progression.

View Figures

View References

1	Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S and Strauss SJ: Incidence and survival of malignant bone sarcomas in England 1979–2007. Int J Cancer. 131:E508–E517. 2012. View Article : Google Scholar : PubMed/NCBI
2	Grunewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Álava E, Kovar H, Sorensen PH, Delattre O and Dirksen U: Ewing sarcoma. Nat Rev Dis Primers. 4:52018. View Article : Google Scholar : PubMed/NCBI
3	Stahl M, Ranft A, Paulussen M, Bölling T, Vieth V, Bielack S, Görtitz I, Braun-Munzinger G, Hardes J, Jürgens H and Dirksen U: Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 57:549–553. 2011. View Article : Google Scholar : PubMed/NCBI
4	Burchill SA: Ewing's sarcoma: Diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol. 56:96–102. 2003. View Article : Google Scholar : PubMed/NCBI
5	Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvà ML, Rossetti NE, Boonseng WE, Oksuz O, Cook EB, et al: EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 26:668–681. 2014. View Article : Google Scholar : PubMed/NCBI
6	Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ and Lessnick SL: Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. 32:5089–5100. 2013. View Article : Google Scholar : PubMed/NCBI
7	Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL and Beckerle MC: The EWS/FLI oncogene drives changes in cellular morphology, adhesion, and migration in ewing sarcoma. Genes Cancer. 3:102–116. 2012. View Article : Google Scholar : PubMed/NCBI
8	Fadul J, Bell R, Hoffman LM, Beckerle MC, Engel ME and Lessnick SL: EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma. Genes Cancer. 6:129–143. 2015.PubMed/NCBI
9	Pedersen EA, Menon R, Bailey KM, Thomas DG, Van Noord RA, Tran J, Wang H, Qu PP, Hoering A, Fearon ER, et al: Activation of Wnt/β-catenin in ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states. Cancer Res. 76:5040–5053. 2016. View Article : Google Scholar : PubMed/NCBI
10	de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, et al: EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol. 16:1248–1255. 1998. View Article : Google Scholar : PubMed/NCBI
11	Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, et al: Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: Prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol. 28:1982–1988. 2010. View Article : Google Scholar : PubMed/NCBI
12	van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, et al: Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol. 28:1989–1994. 2010. View Article : Google Scholar : PubMed/NCBI
13	Langfelder P and Horvath S: WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
14	Saris CG, Horvath S, van Vught PW, van Es MA, Blauw HM, Fuller TF, Langfelder P, DeYoung J, Wokke JH, Veldink JH, et al: Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. BMC Genomics. 10:4052009. View Article : Google Scholar : PubMed/NCBI
15	Savola S, Klami A, Myllykangas S, Manara C, Scotlandi K, Picci P, Knuutila S and Vakkila J: High expression of complement component 5 (C5) at tumor site associates with superior survival in Ewing's sarcoma family of tumour patients. ISRN Oncol 2011. 1687122011.
16	M K: Post-genome informatics. 2000.PubMed/NCBI
17	Volchenboum SL, Andrade J, Huang L, Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U, Triche TJ and Lawlor ER: Gene expression profiling of ewing sarcoma tumors reveals the prognostic importance of tumor-stromal interactions: A report from the Children's oncology group. J Pathol Clin Res. 1:83–94. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kovar H, Dworzak M, Strehl S, Schnell E, Ambros IM, Ambros PF and Gadner H: Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene. 5:1067–1070. 1990.PubMed/NCBI
19	Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, et al: Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 40:616–622. 2008. View Article : Google Scholar : PubMed/NCBI
20	Liu P, Vikis HG, Wang D, Lu Y, Wang Y, Schwartz AG, Pinney SM, Yang P, de Andrade M, Petersen GM, et al: Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst. 100:1326–1330. 2008. View Article : Google Scholar : PubMed/NCBI
21	Wang T, Chen T, Thakur A, Liang Y, Gao L, Zhang S, Tian Y, Jin T, Liu JJ and Chen M: Association of PSMA4 polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population. Clin Transl Oncol. 17:564–569. 2015. View Article : Google Scholar : PubMed/NCBI
22	Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, Rammensee HG, Koszinowski UH and Kloetzel PM: A role for the proteasome regulator PA28alpha in antigen presentation. Nature. 381:166–168. 1996. View Article : Google Scholar : PubMed/NCBI
23	Rut W and Drag M: Human 20S proteasome activity towards fluorogenic peptides of various chain lengths. Biol Chem. 397:921–926. 2016. View Article : Google Scholar : PubMed/NCBI
24	Yano M, Koumoto Y, Kanesaki Y, Wu X and Kido H: 20S proteasome prevents aggregation of heat-denatured proteins without PA700 regulatory subcomplex like a molecular chaperone. Biomacromolecules. 5:1465–1469. 2004. View Article : Google Scholar : PubMed/NCBI
25	Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, et al: MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 10(pii): eaar33422018. View Article : Google Scholar : PubMed/NCBI
26	Nakayama M: Antigen presentation by MHC-dressed cells. Front Immunol. 5:6722014.PubMed/NCBI
27	Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M and Altevogt P: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 362:869–875. 2003. View Article : Google Scholar : PubMed/NCBI
28	Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P and Gutwein P: L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett. 189:237–247. 2003. View Article : Google Scholar : PubMed/NCBI
29	Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, et al: L1CAM in early-stage type I endometrial cancer: Results of a large multicenter evaluation. J Natl Cancer Inst. 105:1142–1150. 2013. View Article : Google Scholar : PubMed/NCBI
30	Altevogt P, Doberstein K and Fogel M: L1CAM in human cancer. Int J Cancer. 138:1565–1576. 2016. View Article : Google Scholar : PubMed/NCBI
31	Geismann C, Morscheck M, Koch D, Bergmann F, Ungefroren H, Arlt A, Tsao MS, Bachem MG, Altevogt P, Sipos B, et al: Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: Role in malignant transformation of pancreatic cancer. Cancer Res. 69:4517–4526. 2009. View Article : Google Scholar : PubMed/NCBI
32	Schafer H, Struck B, Feldmann EM, Bergmann F, Grage-Griebenow E, Geismann C, Ehlers S, Altevogt P and Sebens S: TGF-β1-dependent L1CAM expression has an essential role in macrophage-induced apoptosis resistance and cell migration of human intestinal epithelial cells. Oncogene. 32:180–189. 2013. View Article : Google Scholar : PubMed/NCBI
33	Finas D, Huszar M, Agic A, Dogan S, Kiefel H, Riedle S, Gast D, Marcovich R, Noack F, Altevogt P, et al: L1 cell adhesion molecule (L1CAM) as a pathogenetic factor in endometriosis. Hum Reprod. 23:1053–1062. 2008. View Article : Google Scholar : PubMed/NCBI
34	Datta PK and Moses HL: STRAP and Smad7 synergize in the inhibition of transforming growth factor beta signaling. Mol Cell Biol. 20:3157–3167. 2000. View Article : Google Scholar : PubMed/NCBI
35	Halder SK, Anumanthan G, Maddula R, Mann J, Chytil A, Gonzalez AL, Washington MK, Moses HL, Beauchamp RD and Datta PK: Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis. Cancer Res. 66:6156–6166. 2006. View Article : Google Scholar : PubMed/NCBI
36	Pruksakorn D, Klangjorhor J, Lirdprapamongkol K, Teeyakasem P, Sungngam P, Chaiyawat P, Phanphaisarn A, Settakorn J and Srisomsap C: Oncogenic roles of serine-threonine kinase receptor-associated protein (STRAP) in osteosarcoma. Cancer Chemother Pharmacol. 82:1039–1047. 2018. View Article : Google Scholar : PubMed/NCBI
37	Chen G, Deng C and Li YP: TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 8:272–288. 2012. View Article : Google Scholar : PubMed/NCBI
38	Franchi A, Arganini L, Baroni G, Calzolari A, Capanna R, Campanacci D, Caldora P, Masi L, Brandi ML and Zampi G: Expression of transforming growth factor beta isoforms in osteosarcoma variants: Association of TGF beta 1 with high-grade osteosarcomas. J Pathol. 185:284–289. 1998. View Article : Google Scholar : PubMed/NCBI
39	Nissenbaum J, Devor M, Seltzer Z, Gebauer M, Michaelis M, Tal M, Dorfman R, Abitbul-Yarkoni M, Lu Y, Elahipanah T, et al: Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2. Genome Res. 20:1180–1190. 2010. View Article : Google Scholar : PubMed/NCBI
40	Liu YL, Fann CS, Liu CM, Chen WJ, Wu JY, Hung SI, Chen CH, Jou YS, Liu SK, Hwang TJ, et al: RASD2, MYH9, and CACNG2 genes at chromosome 22q12 associated with the subgroup of schizophrenia with non-deficit in sustained attention and executive function. Biol Psychiatry. 64:789–796. 2008. View Article : Google Scholar : PubMed/NCBI
41	Yoo Y, Jung J, Lee YN, Lee Y, Cho H, Na E, Hong J, Kim E, Lee JS, Lee JS, et al: GABBR2 mutations determine phenotype in rett syndrome and epileptic encephalopathy. Ann Neurol. 82:466–478. 2017. View Article : Google Scholar : PubMed/NCBI
42	Philpott AL, Fitzgerald PB, Bailey NW, Churchyard A, Georgiou-Karistianis N and Cummins TD: A GABBR2 gene variant modifies pathophysiology in Huntington's disease. Neurosci Lett. 620:8–13. 2016. View Article : Google Scholar : PubMed/NCBI